Oncostatin M, leukemia inhibitory factor, and interleukin 6 induce the proliferation of human plasmacytoma cells via the common signal transducer, gp130

doi:10.1084/jem.179.4.1343

This Article

	Full Text (PDF, 528K)
	Alert me when this article is cited
	Citation Map

Services

	Email this article
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new content in the JEM
	Download to citation manager

Citing Articles

	Citing Articles via HighWire
	Citing Articles via CrossRef
	Citing Articles via Google Scholar

Google Scholar

	Articles by Nishimoto, N.
	Articles by Kishimoto, T.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Nishimoto, N.
	Articles by Kishimoto, T.


Social Bookmarking

	What's this?

ARTICLES

Oncostatin M, leukemia inhibitory factor, and interleukin 6 induce the proliferation of human plasmacytoma cells via the common signal transducer, gp130

N Nishimoto, A Ogata, Y Shima, Y Tani, H Ogawa, M Nakagawa, H Sugiyama, K Yoshizaki and T Kishimoto
Department of Medicine III, Osaka University Medical School, Japan.

We analyzed the stimulatory effect of oncostatin M (OSM), leukemia inhibitory factor (LIF), interleukin 6 (IL-6), IL-11, and the inhibitory effect of anti-IL-6 antibody (Ab), anti-IL-6 receptor monoclonal antibody (mAb), and anti-gp130 mAb on the growth of human plasmacytoma cells freshly isolated from a patient with multiple myeloma. The purified cells showed a plasmacytoid morphology and expressed CD38, CD54, and CD56 antigens but no CD3, CD5, CD10, CD19, CD20, or very late antigen 5. IL-6 receptor (IL-6R) and its signal transducer, gp130, were expressed on their cell surface at a low level. Dose-dependent proliferation of the cells in response to OSM, LIF, and IL-6, but not to IL-11, was observed using [3H]TdR incorporation in vitro. Both anti-IL-6 Ab and anti-IL-6R mAb inhibited the growth of the cells in the presence or absence of exogenous IL-6. These cells release IL-6 but not OSM or LIF into the culture supernatant during short-term culture. Therefore, an autocrine growth mechanism mediated by IL-6, but not by OSM or LIF, was confirmed. Furthermore, anti-gp130 mAb completely inhibited the proliferation of the cells induced by OSM, LIF, as well as IL-6. These data indicate that OSM, LIF, and IL-6 can act as growth factors of human plasmacytoma cells through a common signal transducer, gp130, on their cell surface, and also suggest the potential therapeutic application of anti-gp130 mAb, as well as anti-IL- 6R mAb against myeloma/plasmacytomas.
Add to CiteULike CiteULike Add to Complore Complore Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Add to Reddit Reddit Add to Technorati Technorati What's this?

This article has been cited by other articles:

Hideshima, T., Bergsagel, P. L., Kuehl, W. M., Anderson, K. C. (2004). Advances in biology of multiple myeloma: clinical applications. Blood 104: 607-618 [Abstract] [Full Text]
Rawstron, A. C., Fenton, J. A. L., Ashcroft, J., English, A., Jones, R. A., Richards, S. J., Pratt, G., Owen, R., Davies, F. E., Child, J. A., Jack, A. S., Morgan, G. (2000). The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells. Blood 96: 3880-3886 [Abstract] [Full Text]
Nishimoto, N., Kishimoto, T., Yoshizaki, K. (2000). Anti-interleukin 6 receptor antibody treatment in rheumatic disease. Ann Rheum Dis 59: i21-27 [Abstract] [Full Text]
Auernhammer, C. J., Melmed, S. (2000). Leukemia-Inhibitory Factor--Neuroimmune Modulator of Endocrine Function. Endocr. Rev. 21: 313-345 [Abstract] [Full Text]
Nishimoto, N., Ito, A., Ono, M., Tagoh, H., Matsumoto, T., Tomita, T., Ochi, T., Yoshizaki, K. (2000). IL-6 inhibits the proliferation of fibroblastic synovial cells from rheumatoid arthritis patients in the presence of soluble IL-6 receptor. Int Immunol 12: 187-193 [Abstract] [Full Text]
Nishimoto, N., Sasai, M., Shima, Y., Nakagawa, M., Matsumoto, T., Shirai, T., Kishimoto, T., Yoshizaki, K. (2000). Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 95: 56-61 [Abstract] [Full Text]
Liu, J., Li, C., Ahlborn, T. E., Spence, M. J., Meng, L., Boxer, L. M. (1999). The Expression of p53 Tumor Suppressor Gene in Breast Cancer Cells Is Down-Regulated by Cytokine Oncostatin M. Cell Growth Differ. 10: 677-683 [Abstract] [Full Text]
Reznikov, L. L., Puren, A. J., Fantuzzi, G., Hamner, G. R., Schwertschlag, U. S., Ryan, J. L., Dinarello, C. A. (1999). Suppression of endotoxin-inducible cytokines in whole blood from human subjects following single dose of recombinant human interleukin-11. Innate Immunity 5: 197-204 [Abstract]
Zhang, Y., Willson, T., Metcalf, D., Cary, D., Hilton, D. J., Clark, R., Nicola, N. A. (1998). The Box-1 Region of the Leukemia Inhibitory Factor Receptor alpha -Chain Cytoplasmic Domain Is Sufficient for Hemopoietic Cell Proliferation and Differentiation. J. Biol. Chem. 273: 34370-34383 [Abstract] [Full Text]
Barille, S., Akhoundi, C., Collette, M., Mellerin, M.-P., Rapp, M.-J., Harousseau, J.-L., Bataille, R., Amiot, M. (1997). Metalloproteinases in Multiple Myeloma: Production of Matrix Metalloproteinase-9 (MMP-9), Activation of proMMP-2, and Induction of MMP-1 by Myeloma Cells. Blood 90: 1649-1655 [Abstract] [Full Text]
Du, X., Williams, D. A. (1997). Interleukin-11: Review of Molecular, Cell Biology, and Clinical Use. Blood 89: 3897-3908 [Full Text]
Gonda, T. J., D'Andrea, R. J. (1997). Activating Mutations in Cytokine Receptors: Implications for Receptor Function and Role in Disease. Blood 89: 355-369 [Full Text]
Pernis, A., Gupta, S., Yopp, J., Garfein, E., Kashleva, H., Schindler, C., Rothman, P. (1995). [IMAGE]Chain-associated Cytokine Receptors Signal through Distinct Transducing Factors. J. Biol. Chem. 270: 14517-14522 [Abstract] [Full Text]